GlucoTrack (GCTK) Competitors $0.29 +0.07 (+30.81%) (As of 12/20/2024 05:51 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends GCTK vs. NUWE, POAI, AEMD, CTCX, SINT, STSS, CHEK, AMIX, HSCS, and QNRXShould you be buying GlucoTrack stock or one of its competitors? The main competitors of GlucoTrack include Nuwellis (NUWE), Predictive Oncology (POAI), Aethlon Medical (AEMD), Carmell (CTCX), Sintx Technologies (SINT), Sharps Technology (STSS), Check-Cap (CHEK), Autonomix Medical (AMIX), Heart Test Laboratories (HSCS), and Quoin Pharmaceuticals (QNRX). These companies are all part of the "medical equipment" industry. GlucoTrack vs. Nuwellis Predictive Oncology Aethlon Medical Carmell Sintx Technologies Sharps Technology Check-Cap Autonomix Medical Heart Test Laboratories Quoin Pharmaceuticals GlucoTrack (NASDAQ:GCTK) and Nuwellis (NASDAQ:NUWE) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, media sentiment, community ranking, dividends, risk, institutional ownership and earnings. Which has preferable valuation and earnings, GCTK or NUWE? GlucoTrack has higher earnings, but lower revenue than Nuwellis. GlucoTrack is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGlucoTrackN/AN/A-$7.10M-$2.83-0.10Nuwellis$8.97M0.49-$20.21M-$116.41-0.01 Which has more risk and volatility, GCTK or NUWE? GlucoTrack has a beta of -0.17, meaning that its stock price is 117% less volatile than the S&P 500. Comparatively, Nuwellis has a beta of 0.32, meaning that its stock price is 68% less volatile than the S&P 500. Is GCTK or NUWE more profitable? GlucoTrack has a net margin of 0.00% compared to Nuwellis' net margin of -169.54%. GlucoTrack's return on equity of -826.43% beat Nuwellis' return on equity.Company Net Margins Return on Equity Return on Assets GlucoTrackN/A -826.43% -707.26% Nuwellis -169.54%-28,159.25%-207.24% Do analysts rate GCTK or NUWE? Nuwellis has a consensus price target of $17.00, suggesting a potential upside of 1,600.00%. Given Nuwellis' stronger consensus rating and higher possible upside, analysts plainly believe Nuwellis is more favorable than GlucoTrack.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GlucoTrack 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Nuwellis 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Does the media favor GCTK or NUWE? In the previous week, Nuwellis had 3 more articles in the media than GlucoTrack. MarketBeat recorded 4 mentions for Nuwellis and 1 mentions for GlucoTrack. GlucoTrack's average media sentiment score of 1.80 beat Nuwellis' score of 0.00 indicating that GlucoTrack is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GlucoTrack 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Nuwellis 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals hold more shares of GCTK or NUWE? 10.9% of GlucoTrack shares are owned by institutional investors. Comparatively, 3.1% of Nuwellis shares are owned by institutional investors. 46.5% of GlucoTrack shares are owned by company insiders. Comparatively, 2.6% of Nuwellis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the MarketBeat Community prefer GCTK or NUWE? Nuwellis received 22 more outperform votes than GlucoTrack when rated by MarketBeat users. CompanyUnderperformOutperformGlucoTrackN/AN/ANuwellisOutperform Votes2253.66% Underperform Votes1946.34% SummaryNuwellis beats GlucoTrack on 10 of the 17 factors compared between the two stocks. Ad Behind the Markets⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Click here for the ticker >>> Get GlucoTrack News Delivered to You Automatically Sign up to receive the latest news and ratings for GCTK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GCTK vs. The Competition Export to ExcelMetricGlucoTrackSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.67M$4.34B$5.14B$9.08BDividend YieldN/A44.57%5.09%4.23%P/E Ratio-0.1025.0190.0517.20Price / SalesN/A45.901,117.09117.04Price / CashN/A43.4443.1037.85Price / Book0.387.094.784.78Net Income-$7.10M$13.64M$120.31M$225.60M7 Day Performance12.36%-2.93%-1.92%-1.23%1 Month Performance11.58%-1.42%13.65%0.46%1 Year Performance-79.14%39.20%28.34%15.24% GlucoTrack Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GCTKGlucoTrack1.6869 of 5 stars$0.29+30.8%N/A-77.5%$4.71MN/A-0.105News CoveragePositive NewsGap UpHigh Trading VolumeNUWENuwellis1.6311 of 5 stars$1.19+0.8%$17.00+1,328.6%-95.0%$5.20M$8.86M-0.0159News CoveragePositive NewsPOAIPredictive Oncology2.2462 of 5 stars$0.75-3.8%$3.00+300.0%-76.7%$5M$1.48M-0.2530News CoverageGap UpAEMDAethlon Medical3.0781 of 5 stars$0.35-2.8%$7.00+1,924.3%-69.3%$4.83M$570,000.00-0.1310Analyst ForecastNews CoverageCTCXCarmell1.2672 of 5 stars$0.22+4.8%N/A-94.5%$4.53M$32,839.000.0014News CoveragePositive NewsSINTSintx Technologies0.4811 of 5 stars$3.03-2.3%N/A-95.3%$4.07M$1.64M-0.0643STSSSharps Technology1.0349 of 5 stars$2.13+4.4%N/AN/A$3.83MN/A-0.263News CoveragePositive NewsCHEKCheck-Cap0.344 of 5 stars$0.62-1.6%N/A-71.4%$3.60MN/A-0.2180Analyst ForecastNews CoverageGap DownAMIXAutonomix Medical2.9131 of 5 stars$3.12-2.2%$28.00+797.4%N/A$3.59MN/A-0.201News CoverageHSCSHeart Test Laboratories2.2783 of 5 stars$3.85+2.1%$15.00+289.6%-75.7%$3.52M$18,600.00-0.1810Earnings ReportAnalyst ForecastNews CoverageGap UpQNRXQuoin Pharmaceuticals2.9084 of 5 stars$0.64-3.0%$4.00+524.9%-86.3%$3.23MN/A-0.164News CoverageGap Down Related Companies and Tools Related Companies NUWE Alternatives POAI Alternatives AEMD Alternatives CTCX Alternatives SINT Alternatives STSS Alternatives CHEK Alternatives AMIX Alternatives HSCS Alternatives QNRX Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GCTK) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GlucoTrack, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GlucoTrack With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
